Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

ABSTRACT: A derivative cell line of HCT116, HML58-3, was established to detect DNA demethylating agents [Okochi-Takada E, Epigenetics. 2018;13:147-55.]. HML58-3 cells were treated with DNA demethylating agents (decitabine, OR-2003, and OR-2100) or mock. A genome-wide gene expression analysis was performed using SurePrint G3 Human Gene Expression 8 x 60K v2 Microarray.

ORGANISM(S): Homo sapiens

PROVIDER: GSE134294 | GEO | 2019/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide DNA demethylation of HML58-3 (a derivative cell line of HCT116) after treatment of DAC, OR-2003, and OR-2100

Project description:A derivative cell line of HCT116, HML58-3, was established to detect DNA demethylating agents [Okochi-Takada E, Epigenetics. 2018;13:147-55.]. HML58-3 cells were treated with DNA demethylating agents (DAC, OR-2003, and OR-2100). Genome-wide DNA methylation was analyzed using the Infinium Human MethylationEPIC BeadChip.

2019-08-01 | GSE134293 | GEO

Genome-wide gene expression of NB-1 after treatment of 5-aza-dC, TBT, and combination

Project description:A neuroblastoma cell line, NB-1, was treated with mock, a DNA demethylating agent (5-aza-2'-deoxycytidine: 5-aza-dC), a synthetic retinoic acid (tamibarotene: TBT), and the combination of 5-aza-dC and TBT. A genome-wide gene expression analysis was performed using SurePrint G3 Human Gene Expression 8 x 60K v2 Microarray.

2021-07-23 | GSE180645 | GEO

Gene expression profile of K562 and KBM5 treated with the combination of imatinib and a new demethylating agent, OR-2100

Project description:Treatment with demethylating agents in combination with tyrosine kinase inhibitors have shown improved molecular responses and survival benefits in patients with TKI-resistant or advanced-phase CML. However, little is known regarding underlying mechanism of the combination anti-tumor effect of demethylating agents and tyrosine kinase inhibitors. To analyze the combination effect, we have compared gene expression profiles among chronic myeloid leukemia (CML) cell lines (K562, KBM5) treated with imatinib (IM), a new demethylating agent, OR-2100 (OR21), and these combination therapy.

2020-09-09 | GSE157620 | GEO

The impact of decitabine treatment in MDS-induced Tet2KD/KDEzh2Δ/Δ LSK HSPCs

Project description:To evaluate the impact of DNA demethylating agents on our mouse MDS model, we chose 5-aza-2’-deoxycytidine, decitabine (DAC), one of the DNA demethylating agents, which is incorporated into DNA but not RNA and has 10-fold more potency in DNA demethylation than 5-azacitidine. We transplanted Tet2KD/KDEzh2Δ/Δ MDS cells into lethally irradiated secondary recipients and treated them with DAC (low dose DAC at 0.25mg/kg, 3 times a week, intraperitoneal injection), then purified LSK HSPCs and evaluated the expression profiles.

2017-03-15 | GSE79204 | GEO

microRNA expression profiling of paired primary and lymph node metastatic breast cancer patients

Project description:Extracted total RNA from FFPE tissue were used for RNA labeling and hybridization on to the Agilent Human SurePrint 8 × 60k v16 miRNA microarray chip according to the manufacturer's protocol.

2020-05-31 | GSE148846 | GEO

Agilent SurePrint G3 Mouse GE V2.0 Microarray(8*60K,Design ID:074809)

Project description:Agilent SurePrint G3 Mouse GE V2.0 Microarray(8*60K,Design ID:074809)

| PRJNA699158 | ENA

Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

Project description:Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

| PRJNA554657 | ENA

gene expression of KYSE510 cells with treatment of 100 nM PAF for 24 hours

Project description:KYSE510 cells were treated with 100 nM PAF for 24 hours,and then KYSE510 cells were collected for gene expression analysis using Agilent SurePrint G3 Human Gene Expression v3 (8×60K) Microarray. Investigation of the gene network of KYSE510 cells regulated by PAF.

2023-12-16 | GSE163355 | GEO

Gene expression of KYSE410 cells with treatment of 10 uM FAK inhibitor (defactinib) for 4 hours and 24 hours

Project description:KYSE410 cells were treated with 10 uM defactinib for 4 hours and 24 hours,and KYSE410 cells were collected for gene expression analysis using Agilent SurePrint G3 Human Gene Expression v3 (8×60K) Microarray. Investigation of the critical gene of KYSE410 cells treated by defactinib.

2022-07-07 | GSE155591 | GEO

SMARCA4 reads PRMT1-mediated H4R3me2a to promote colorectal cancer progression II

Project description:To further investigate the functional associations between PRMT1 and SMARCA4 and explore the biological significance of these interactions, we conducted expression profiling on the Agilent SurePrint G3 Human Gene Expression v3 (8*60K,Design ID:072363) using knockdown of PRMT1 or SMARCA4’s RNA in HCT116 cells.

2020-01-07 | GSE143199 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data